REVIEW 2 cited by
A Transformer-based Generative Model for De Novo Molecular Design
Not yet reviewed by Pith; the record is open.
This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.
SPECIMEN: schema-true, not a live event
T0 review · schema-true
One-sentence machine reading of the paper's core claim.
pith:XXXXXXXX · record.json · timestamp
read the original abstract
In the scope of drug discovery, the molecular design aims to identify novel compounds from the chemical space where the potential drug-like molecules are estimated to be in the order of 10^60 - 10^100. Since this search task is computationally intractable due to the unbounded search space, deep learning draws a lot of attention as a new way of generating unseen molecules. As we seek compounds with specific target proteins, we propose a Transformer-based deep model for de novo target-specific molecular design. The proposed method is capable of generating both drug-like compounds (without specified targets) and target-specific compounds. The latter are generated by enforcing different keys and values of the multi-head attention for each target. In this way, we allow the generation of SMILES strings to be conditional on the specified target. Experimental results demonstrate that our method is capable of generating both valid drug-like compounds and target-specific compounds. Moreover, the sampled compounds from conditional model largely occupy the real target-specific molecules' chemical space and also cover a significant fraction of novel compounds.
Forward citations
Cited by 2 Pith papers
-
Phenotypic Profile-Informed Generation of Drug-Like Molecules via Dual-Channel Variational Autoencoders
SmilesGEN generates drug-like molecules from gene expression profiles by subtracting the molecule's latent code from the treated-cell code to reconstruct the untreated cell state.
-
ScaffoldGPT: A Scaffold-based GPT Model for Drug Optimization
A scaffold-prompted GPT with two-phase pretraining, reinforcement fine-tuning, and reward-guided decoding reports improved drug-optimization scores on COVID and cancer benchmarks, though evaluation and training share ...
Discussion (0). Continue with ORCID to comment.